Phraxis Unveils EndoForce™ Anastomotic Connector's Milestone Use
Phraxis, Inc. has recently made headlines with the successful launch of its EndoForce™ Anastomotic Connector. This innovative device marks a turning point in the treatment options available for dialysis patients worldwide. The completion of the first commercial case signifies not just a technological advancement but an important shift in how vascular access surgery might be approached.
Significance of the EndoForce™ Anastomotic Connector
The procedure was performed by Dr. Ari Kramer, a renowned vascular access surgeon and an early advocate of the EndoForce™ device. The fact that this groundbreaking procedure happened at a leading medical facility underscores the importance of the event. The EndoForce™ Connector is designed to replace traditional hand-sewn sutures, simplifying the vascular access creation process and yielding predictable results.
Innovative Technology for Enhanced Patient Outcomes
This remarkable technology received U.S. Food and Drug Administration (FDA) approval and represents the first of its kind designed specifically to facilitate vascular access. Compatible with all PTFE grafts, the EndoForce™ has been tested thoroughly in pivotal clinical trials, reassuring medical professionals about its efficacy and safety.
Physician Insights on the New Device
Dr. Kramer stated, "Every decision we make in the OR comes back to the patient. With EndoForce™, we have a tool designed to make graft-to-vein connections more predictable and efficient." His commitment to enhancing patient care is evident in this positive step for the dialysis community.
The Journey of Development and Innovation
Phraxis, Inc. is proud to highlight that this achievement culminates from over a decade of tireless effort, innovative thinking, and collaboration with some of the most proficient surgeons in the field. Dr. Alex Yevzlin, the Founder and CEO of Phraxis, expressed that he is thrilled to see the EndoForce™ begin its clinical journey, emphasizing its potential to significantly improve patient outcomes.
A New Era in Vascular Access Surgery
According to Geoffrey Beecher, Chief Commercial Officer, "Today represents more than a first commercial case—it's the beginning of a new standard in vascular access surgery. Dialysis patients deserve consistent, reliable solutions, and EndoForce is designed to deliver on that promise." The initiative marks the official commencement of U.S. commercialization for the device, which is anticipated at numerous clinical sites across the country in the near future.
About Phraxis, Inc.
Phraxis, Inc. is based in Minneapolis, Minnesota, and is dedicated to advancing vascular access techniques for dialysis patients. The flagship EndoForce™ Anastomotic Connector stands out as a significant innovation that provides surgeons with an efficient alternative to traditional methods, ultimately aiming to enhance patient recovery and outcomes.
Frequently Asked Questions
What is the EndoForce™ Anastomotic Connector?
The EndoForce™ Anastomotic Connector is a medical device designed to simplify vascular access creation for dialysis patients by replacing traditional sutures.
Who performed the first commercial case?
The first commercial case using the EndoForce™ Connector was performed by Dr. Ari Kramer, a vascular access surgeon.
How does the EndoForce™ improve surgical procedures?
This device offers a standardized approach that enhances the predictability and efficiency of graft-to-vein connections in surgery.
What recognition has the EndoForce™ received?
The EndoForce™ has gained FDA approval, validating its safety and efficacy as a novel device in vascular access surgery.
What are Phraxis, Inc.'s future plans for EndoForce™?
Phraxis plans to collaborate with leading vascular surgeons and expand its availability, with more clinical sites expected to start using the device soon.
